PML and acute promyelocytic leukemia: ATO has no therapeutic potential on different subtypes of APL (PLZF-RARα–driven APL), due to the fact that the therapeutic efficiency of this drug is dictated by its binding to the PML moiety of PML-RARα [18,19].